<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946734</url>
  </required_header>
  <id_info>
    <org_study_id>SPRING2021</org_study_id>
    <nct_id>NCT04946734</nct_id>
  </id_info>
  <brief_title>Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine</brief_title>
  <acronym>SPRING</acronym>
  <official_title>Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine （SPRING）: a Multicenter, Random, Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effectivity and safety of PFO closure vs medicine in alleviating migraine （SPRING）: a&#xD;
      multicenter, random, case control study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cessation of migraine</measure>
    <time_frame>Month 12</time_frame>
    <description>Primary Efficacy Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Event (SAE) related due to device, drug or study procedure</measure>
    <time_frame>Month 12</time_frame>
    <description>Primary Safety Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monthly migraine attacks</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Mean change of monthly migraine attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly migraine days</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Mean change of monthly migraine days. Monthly migraine days = migraine attacks in one month × average time period per attacks (hours) /24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Percentage of subject with at least 50% reduction in monthly migraine attacks from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>PFO - Patent Foramen Ovale</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device PFO closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drugs only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PFO closure device</intervention_name>
    <description>Device PFO closure.</description>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and clopidogrel</intervention_name>
    <description>Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptans</intervention_name>
    <description>If migraine recurred, Triptans would be administered during the acute phase.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Presence of PFO with right-to-left shunt, confirmed by Transthoracic.&#xD;
&#xD;
          2. Echocardiography (TTE) or transesophageal echocardiography (TEE) with a bubble study.&#xD;
&#xD;
          3. Bubble study positive confirmed by transcranial doppler.&#xD;
&#xD;
          4. Subject is diagnosed of migraine.&#xD;
&#xD;
          5. Subject signs an informed Consent Form and is willing to participate in follow-up&#xD;
             visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is diagnosed of headache with clear etiology.&#xD;
&#xD;
          2. Subject had cerebral hemorrhage, bleeding events in other organs within 3 months or&#xD;
             was in high risk of bleeding.&#xD;
&#xD;
          3. Brain CT/MR showed ischemic lesions.&#xD;
&#xD;
          4. Subject is diagnosed of hepatic insufficiency: ALT or AST&gt;3×ULN at the screening&#xD;
             visit.&#xD;
&#xD;
          5. Subject is diagnosed of moderate to severe renal insufficiency: eGFR&lt;30ml/min/1.73m2&#xD;
             at the screening visit.&#xD;
&#xD;
          6. Subject has uncontrolled arrhythmia with clinical significance within 90 days.&#xD;
&#xD;
          7. Subject is diagnosed of unstable angina, severe coronary atherosclerosis or myocardial&#xD;
             infarction within 90 days.&#xD;
&#xD;
          8. Subject is diagnosed of pulmonary artery embolism, peripheral artery embolism or deep&#xD;
             Vein Thrombosis.&#xD;
&#xD;
          9. Subject cannot follow the study procedure due to other acute or chronic diseases.&#xD;
&#xD;
         10. Subject is pregnant or lactating.&#xD;
&#xD;
         11. Subject is under other RCT.&#xD;
&#xD;
         12. Subject has a life expectancy &lt;1 year.&#xD;
&#xD;
         13. Subject cannot follow the study procedure due to other reasons in the opinion of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Caojin, MD</last_name>
    <phone>83827812</phone>
    <email>yszcj74@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhang Caojin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Caojin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The deidentified participant data will be shared on a request basis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

